|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In a word, TMPO-AS1 serves as a competing endogenous RNA to boost osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis, which provided an underlying therapeutic target for patients with OS.
|
31680323 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of TMPO-AS1, TMPO mRNA and protein levels were associated with tumor progression of NSCLC.
|
31230752 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, dysregulation of lncRNA-SIGLEC17P, GGTA1P, A2M-AS1, LINC00938, GVINP1, LINC00667 and TMPO-AS1 was associated with overall survival time in patients with NSCLC.
|
31423174 |
2019 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The upregulation of TMPO-AS1, TMPO mRNA and protein levels were associated with tumor progression of NSCLC.
|
31230752 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our findings indicate that TMPO-AS1 contributes to lung carcinogenesis, which may be partially through upregulation TMPO.
|
31230752 |
2019 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
|
30105831 |
2018 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our present study elucidated that a remarkable overexpression of TMPO-AS1 was found in OS tissues and cells.
|
31680323 |
2020 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our present study elucidated that a remarkable overexpression of TMPO-AS1 was found in OS tissues and cells.
|
31680323 |
2020 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our present study elucidated that a remarkable overexpression of TMPO-AS1 was found in OS tissues and cells.
|
31680323 |
2020 |
|
Malignant tumor of cervix
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TMPO-AS1 was highly expressed in CC.In addition, TMPO-AS1 knockdown inhibited proliferation and migration, and also induced apoptosis.
|
31483914 |
2019 |
|
Cervix carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TMPO-AS1 was highly expressed in CC.In addition, TMPO-AS1 knockdown inhibited proliferation and migration, and also induced apoptosis.
|
31483914 |
2019 |
|
Progression of non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO.
|
31230752 |
2019 |
|
cervical cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TMPO-AS1 was highly expressed in CC.In addition, TMPO-AS1 knockdown inhibited proliferation and migration, and also induced apoptosis.
|
31483914 |
2019 |
|
Multiple malignancy
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In addition, TMPO-AS1 may be a diagnostic and prognostic marker in multiple cancer types.
|
30105831 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Bioinformatics predictions revealed TMPO-AS1 was associated with a series of biological processes involved in PCa progression.
|
30105831 |
2018 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Bioinformatics predictions revealed TMPO-AS1 was associated with a series of biological processes involved in PCa progression.
|
30105831 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on the individual-level DE lncRNAs, we developed a robust prognostic signature consisting of two lncRNA (C1orf132 and TMPO-AS1) for stage I-II LUAD patients without adjuvant therapy (P = 3.06 × 10<sup>-6</sup>, log-rank test), which was confirmed in two independent datasets of GSE50081 (P = 1.82 × 10<sup>-2</sup>, log-rank test) and GSE31210 (P = 7.43 × 10<sup>-4</sup>, log-rank test) after adjusting other clinical factors such as smoking status and stages.
|
28587642 |
2017 |